Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024) Global cancer observatory: cancer today. International Agency for Research on Cancer, Lyon

Google Scholar 

Knight A, Karapetyan L, Kirkwood JM (2023) Immunotherapy in melanoma: recent advances and future directions. Cancers (Basel) 15. https://doi.org/10.3390/cancers15041106

Tan S, Li D, Zhu X (2020) Cancer immunotherapy: pros, cons and beyond. Biomed Pharmacother 124:109821. https://doi.org/10.1016/j.biopha.2020.109821

Article  PubMed  Google Scholar 

Spencer KR, Wang J, Silk AW, Ganesan S, Kaufman HL, Mehnert JM (2016) Biomarkers for immunotherapy: current developments and challenges. Am Soc Clin Oncol Educ Book 35:e493–503. https://doi.org/10.1200/EDBK_160766

Article  PubMed  Google Scholar 

Pavlick AC, Ariyan CE, Buchbinder EI, Davar D, Gibney GT, Hamid O, Hieken TJ, Izar B, Johnson DB, Kulkarni RP et al (2023) Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0. J Immunother Cancer 11:e006947. https://doi.org/10.1136/jitc-2023-006947

Article  PubMed  PubMed Central  Google Scholar 

Garutti M, Bonin S, Buriolla S, Bertoli E, Pizzichetta MA, Zalaudek I, Puglisi F (2021) Find the flame: predictive biomarkers for immunotherapy in melanoma. Cancers (Basel) 13. https://doi.org/10.3390/cancers13081819

Duarte HS, da Veiga CRP, da Veiga CP, Wainstein AJA, da Silva WV, Drummond-Lage AP (2023) Does it fit in your pocket? economic burden of PD-1 inhibitors’ toxicity in the supplementary health system: evidence from Brazil. BMC Health Serv Res 23:781. https://doi.org/10.1186/s12913-023-09736-6

Article  PubMed  PubMed Central  Google Scholar 

Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litiere S, Dancey J, Chen A et al (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18:e143–e152. https://doi.org/10.1016/S1470-2045(17)30074-8

Article  PubMed  PubMed Central  Google Scholar 

Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil CM, Lotem M et al (2019) Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol 20:1239–1251. https://doi.org/10.1016/S1470-2045(19)30388-2

Article  CAS  PubMed  Google Scholar 

Luo J, Wu S, Rizvi H, Zhang Q, Egger JV, Osorio JC, Schoenfeld AJ, Plodkowski AJ, Ginsberg MS, Callahan MK et al (2022) Deciphering radiological stable disease to immune checkpoint inhibitors. Ann Oncol 33:824–835. https://doi.org/10.1016/j.annonc.2022.04.450

Article  CAS  PubMed  Google Scholar 

Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3:RESEARCH0034. https://doi.org/10.1186/gb-2002-3-7-research0034

Article  PubMed  PubMed Central  Google Scholar 

Budczies J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S, Denkert C (2012) Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS ONE 7:e51862. https://doi.org/10.1371/journal.pone.0051862

Article  CAS  PubMed  PubMed Central  Google Scholar 

Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi FS, Martin-Algarra S, Mandal R, Sharfman WH et al (2017) Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 171:934–949.e916. https://doi.org/10.1016/j.cell.2017.09.028

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G et al (2016) Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165:35–44. https://doi.org/10.1016/j.cell.2016.02.065

Article  CAS  PubMed  PubMed Central  Google Scholar 

Danaher P, Warren S, Dennis L, D’Amico L, White A, Disis ML, Geller MA, Odunsi K, Beechem J, Fling SP (2017) Gene expression markers of tumor infiltrating leukocytes. J Immunother Cancer 5:18. https://doi.org/10.1186/s40425-017-0215-8

Article  PubMed  PubMed Central  Google Scholar 

Gene Ontology C, Aleksander SA, Balhoff J, Carbon S, Cherry JM, Drabkin HJ, Ebert D, Feuermann M, Gaudet P, Harris NL et al (2023) The gene ontology knowledgebase in 2023. Genetics 224. https://doi.org/10.1093/genetics/iyad031

D’Angelo A, Kilili H, Chapman R, Generali D, Tinhofer I, Luminari S, Donati B, Ciarrocchi A, Giannini R, Moretto R et al (2023) Immune-related pan-cancer gene expression signatures of patient survival revealed by NanoString-based analyses. PLoS ONE 18:e0280364. https://doi.org/10.1371/journal.pone.0280364

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu J, Liu B, Hu W, Yang Y (2022) A pretreatment transcriptomic signature that predicts outcomes of immunotherapy in melanoma. Heliyon 8:e12648. https://doi.org/10.1016/j.heliyon.2022.e12648

Article  CAS  PubMed  PubMed Central  Google Scholar 

Picornell AC, Echavarria I, Alvarez E, Lopez-Tarruella S, Jerez Y, Hoadley K, Parker JS, Del Monte-Millan M, Ramos-Medina R, Gayarre J et al (2019) Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series. BMC Genomics 20:452. https://doi.org/10.1186/s12864-019-5849-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V et al (2017) IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest 127:2930–2940. https://doi.org/10.1172/JCI91190

Article  PubMed  PubMed Central  Google Scholar 

Hugo W, Shi H, Sun L, Piva M, Song C, Kong X, Moriceau G, Hong A, Dahlman KB, Johnson DB et al (2015) Non-genomic and immune evolution of melanoma acquiring MAPKi resistance. Cell 162:1271–1285. https://doi.org/10.1016/j.cell.2015.07.061

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li X, Wan Z, Liu X, Ou K, Yang L (2022) A 12-chemokine gene signature is associated with the enhanced immunogram scores and is relevant for precision immunotherapy. Med Oncol 39:43. https://doi.org/10.1007/s12032-021-01635-2

Article  CAS  PubMed  Google Scholar 

Sivendran S, Chang R, Pham L, Phelps RG, Harcharik ST, Hall LD, Bernardo SG, Moskalenko MM, Sivendran M, Fu Y et al (2014) Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease. J Invest Dermatol 134:2202–2211. https://doi.org/10.1038/jid.2014.85

Article  CAS  PubMed  PubMed Central  Google Scholar 

Panagiotou E, Syrigos NK, Charpidou A, Kotteas E, Vathiotis IA (2022) CD24: a novel target for cancer immunotherapy. J Pers Med 12. https://doi.org/10.3390/jpm12081235

Bakr MN, Takahashi H, Kikuchi Y (2022) Analysis of melanoma gene expression signatures at the single-cell level uncovers 45-gene signature related to prognosis. Biomedicines 10:1478. https://doi.org/10.3390/biomedicines10071478

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barkal AA, Brewer RE, Markovic M, Kowarsky M, Barkal SA, Zaro BW, Krishnan V, Hatakeyama J, Dorigo O, Barkal LJ et al (2019) CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature 572:392–396. https://doi.org/10.1038/s41586-019-1456-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tang MR, Guo JY, Wang D, Xu N (2018) Identification of CD24 as a marker for tumorigenesis of melanoma. Onco Targets Ther 11:3401–3406. https://doi.org/10.2147/OTT.S157043

Article  PubMed  PubMed Central  Google Scholar 

Tang MR, Wang YX, Guo S, Han SY, Li HH, Jin SF (2014) CD24 expression predicts poor prognosis for patients with cutaneous malignant melanoma. Int J Clin Exp Med 7:4337–4341

PubMed  PubMed Central  Google Scholar 

Gschaider M, Neumann F, Peters B, Lenz F, Cibena M, Goiser M, Wolf I, Wenzel J, Mauch C, Schreiner W et al (2012) An attempt at a molecular prediction of metastasis in patients with primary cutaneous melanoma. PLoS ONE 7:e49865. https://doi.org/10.1371/journal.pone.0049865

Article  CAS  PubMed  PubMed Central